Integrated Wellness · Research education
Compare the science.
Put two to four molecules side by side. Similar goals do not mean similar mechanisms, evidence or risks.
Choose your molecules
4 of 4 selected · Choose at least 2
Explore a comparison:
On smaller screens, scroll the table sideways to see each molecule.
| Research dimension | SS-31 / Elamipretide Human research | MOTS-c Preclinical | Epitalon Preclinical | Humanin Preclinical |
|---|---|---|---|---|
| Biological classification | Elamipretide; mitochondria-targeted tetrapeptide | Mitochondrial-derived 16-amino-acid peptide | Synthetic AEDG tetrapeptide | Mitochondrial-derived peptide |
| Mechanism & pathway | Elamipretide interacts with cardiolipin in the inner mitochondrial membrane. Research examines membrane organization and energy-related function; that mechanism does not by itself demonstrate an anti-aging benefit. | Preclinical work links changes in folate/purine metabolism with AMPK activation and metabolic stress responses. | Synthetic tetrapeptide investigated in Russian longevity research literature for pineal-telomerase signaling. | Investigated as a stress-response signal in cell-survival and apoptosis-related pathways. Mechanisms depend on the experimental model; no clinical neuroprotection effect follows from pathway activity alone. |
| Investigated applications | Mitochondrial membrane function and disease-specific outcomes. | Metabolic stress, insulin sensitivity and skeletal-muscle signaling. | Telomerase, telomere maintenance and pineal-related biology. | Cell survival and neuroprotection hypotheses. |
| Evidence quality | Human research | Preclinical | Preclinical | Preclinical |
| What remains uncertain | Forzinity received accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. A confirmatory trial is required. This is not evidence for healthy-person longevity. | The linked study shows metabolic findings in cells and mice. Human associations with naturally occurring MOTS-c are not evidence that administration improves outcomes. | The linked 2025 study is in human cell lines, including cancer cells—not a human clinical trial or evidence of longer lifespan. | The linked discovery study is laboratory neuroprotection research, not a dementia treatment trial. |
| Safety considerations | Injection-site reactions are common in trials; serious hypersensitivity reactions have been reported. Refer to the approved product label for full contraindications and warnings. | FDA reports no identified human exposure data for nominated MOTS-c drug products and possible immunogenicity and impurity concerns. Endogenous biomarker studies do not establish injection safety. | Long-term safety is unknown. Telomere effects in cancer cell lines are not evidence of cancer treatment or safety. FDA identifies immunogenicity and insufficient safety information. | Human administration, long-term effects and interactions are insufficiently characterized. Endogenous occurrence does not prove a manufactured preparation is safe. |
| Regulatory classification | FDA accelerated approval · Barth syndromeForzinity (elamipretide) received accelerated FDA approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Confirmatory evidence is required. This does not approve longevity use or research-grade SS-31. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. |
Comparing molecules is not a recommendation to combine them. Clinical evidence for one product or indication cannot establish another’s safety or effectiveness. Open each profile for study types, source links and important evidence limitations.